Literature DB >> 23793101

Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system.

Laura Caberlotto1, Lucia Carboni, Floriana Zanderigo, Filippo Andreetta, Michela Andreoli, Gabriella Gentile, Maria Razzoli.   

Abstract

Glycogen synthase kinase (GSK3) is a constitutively active serine-threonine kinase associated to neurological and psychiatric disorders. GSK3 inhibition is considered a mediator of the efficacy of the mood-stabiliser lithium. This study aimed at comparing the central nervous system effect of lithium with the selective GSK3 inhibitors AZ1080 and compound A in biochemical, cellular, and behavioural tests. Collapsin response mediator protein 2 is a neuron-specific GSK3 substrate. Lithium, AZ1080, and compound A inhibited its phosphorylation in rat primary neurons with different pIC50. After systemic treatments with lithium or GSK3 inhibitors to assess specific functional responses, phosphorylation was unchanged in adult rat brain, while it was strongly inhibited by GSK3 inhibitors in pups, differently from lithium. Lithium may exert neurotrophic effect by increasing brain-derived neurotrophic factor (BDNF) levels: in the present experimental conditions, lithium exerted opposite effects on plasma BDNF levels compared to GSK3 inhibitors, suggesting this effect might not be necessarily mediated by GSK3 inhibition alone. While plasma thyroid-stimulating hormone and luteinising hormone were not affected by lithium, they were decreased by selective inhibitors. GH and prolactin displayed similar responses towards reduction. Follicle-stimulating hormone levels were not altered by treatments, whereas melatonin was specifically increased by AZ1080. Lithium impaired mouse spontaneous locomotion and decreased amphetamine-induced hyper-locomotion. AZ1080 had no effects on locomotion, while compound A reduced spontaneous locomotor activity without effects on amphetamine-induced hyper-locomotion. The present results indicate that a broad correlation between the effects of lithium and selective GSK3 inhibitors could not be devised, suggesting alternative mechanisms, whereas overlapping results could be obtained in specific assays.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23793101     DOI: 10.1007/s00210-013-0893-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  66 in total

1.  Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse.

Authors:  Nicole M Enman; Ellen M Unterwald
Journal:  Behav Brain Res       Date:  2012-05-16       Impact factor: 3.332

2.  The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.

Authors:  G Chen; L D Huang; Y M Jiang; H K Manji
Journal:  J Neurochem       Date:  1999-03       Impact factor: 5.372

Review 3.  Validating GSK3 as an in vivo target of lithium action.

Authors:  W Timothy O'Brien; Peter S Klein
Journal:  Biochem Soc Trans       Date:  2009-10       Impact factor: 5.407

4.  Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons.

Authors:  E Chalecka-Franaszek; D M Chuang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Regulation of basal gastric acid secretion by the glycogen synthase kinase GSK3.

Authors:  Anand Rotte; Venkanna Pasham; Melanie Eichenmüller; Wenting Yang; Syed M Qadri; Madhuri Bhandaru; Florian Lang
Journal:  J Gastroenterol       Date:  2010-06-16       Impact factor: 7.527

Review 6.  Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond.

Authors:  Breno Satler Diniz; Antonio Lucio Teixeira
Journal:  Neuromolecular Med       Date:  2011-09-07       Impact factor: 3.843

Review 7.  GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?

Authors:  Ana Martinez; Daniel I Perez
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

8.  Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease.

Authors:  Thomas Leyhe; Gerhard W Eschweiler; Elke Stransky; Thomas Gasser; Peter Annas; Hans Basun; Christoph Laske
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade.

Authors:  Jean-Martin Beaulieu; Tatyana D Sotnikova; Wei-Dong Yao; Lisa Kockeritz; James R Woodgett; Raul R Gainetdinov; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

10.  Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium.

Authors:  Patrizia De Sarno; Xiaohua Li; Richard S Jope
Journal:  Neuropharmacology       Date:  2002-12       Impact factor: 5.250

View more
  6 in total

Review 1.  Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding.

Authors:  Gin S Malhi; Tim Outhred
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

Review 2.  CRMPs: critical molecules for neurite morphogenesis and neuropsychiatric diseases.

Authors:  T T Quach; J Honnorat; P E Kolattukudy; R Khanna; A M Duchemin
Journal:  Mol Psychiatry       Date:  2015-06-16       Impact factor: 15.992

3.  Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats.

Authors:  Sorabh Sharma; Rajeev Taliyan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-12-31       Impact factor: 3.000

4.  Glycogen synthase kinase 3β orchestrates microtubule remodeling in compensatory glomerular adaptation to podocyte depletion.

Authors:  Weiwei Xu; Yan Ge; Zhihong Liu; Rujun Gong
Journal:  J Biol Chem       Date:  2014-12-02       Impact factor: 5.157

5.  Intracerebral Administration of BDNF Protects Rat Brain Against Oxidative Stress Induced by Ouabain in an Animal Model of Mania.

Authors:  Samira S Valvassori; Camila O Arent; Amanda V Steckert; Roger B Varela; Luciano K Jornada; Paula T Tonin; Josiane Budni; Edemilson Mariot; Flávio Kapczinski; João Quevedo
Journal:  Mol Neurobiol       Date:  2014-08-28       Impact factor: 5.590

Review 6.  Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau.

Authors:  Kenneth Hensley; Petri Kursula
Journal:  J Alzheimers Dis       Date:  2016-04-15       Impact factor: 4.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.